RxDoctor Payments Data

Riddhi Shah, MD

Internal Medicine · Middlebury, CTNPI 1710316385

Payments from drug & device makers

$2,625in general payments, 2019–2025

Across 125 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$372
  • Novo Nordisk$358
  • Pfizer$264
  • AbbVie$183
  • Merck$173
  • Lilly USA, LLC$140
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$2,60299%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,625 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$48,178
Medicare patients
142
Services billed
497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin47$52,451
OzempicSemaglutide40$49,914
JanuviaSitagliptin Phosphate47$47,518
InvokanaCanagliflozin14$13,137
XareltoRivaroxaban11$12,221
Tresiba Flextouch U-100Insulin Degludec12$6,368
Breo ElliptaFluticasone/Vilanterol12$4,999
Omega-3 Acid Ethyl Esters21$2,033
Sucralfate15$1,872
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$1,715
SynthroidLevothyroxine Sodium16$1,600
Atorvastatin Calcium233$1,486
Albuterol Sulfate HfaAlbuterol Sulfate73$1,354
Pantoprazole Sodium117$1,238
Levothyroxine Sodium104$1,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$52,45147 claims
Novo NordiskOzempic$358$49,91440 claims
MerckJanuvia$173$47,51847 claims
Johnson & JohnsonInvokana, Xarelto$42$25,35725 claims
GSKBreo Ellipta$372$4,99912 claims
AbbVieSynthroid$183$1,60016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Middlebury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →